Published Nov 10, 2023 05:02AM ET
Achieve Life Sciences (NASDAQ:) has reported significant advancements in the development of cytisinicline, a novel treatment for nicotine dependence, during its recent earnings call. The company has successfully completed Phase 3 trials for smoking and e-cigarette cessation, with a focus on compiling data for New Drug Application (NDA) submission to the FDA. The company’s cash position as of September 30, 2023, was $20 million, sufficient to fund operations until the second half of 2024.
Key takeaways from the earnings call include:
- Achieve Life Sciences has completed clinical studies required for NDA submission and is in the process of compiling the NDA. The company is also having discussions with the FDA and preparing for filing and approval in the U.S.
- The company is exploring potential commercial partnerships and believes the asset should be in the hands of a single global partner with strong U.S. capabilities.
- The company is awaiting data from three supportive studies, expected to be available in the first quarter, which will refine the timing of the NDA submission.
- John Bencich, a representative from the company, stated that discussions with regulatory agencies have been constructive, with agreement reached on many items.
- The company anticipates a decline in spending in the fourth quarter, similar to the decrease seen in the third quarter.
- The company is considering the potential use of the drug for other types of addiction, such as cocaine, and has received interest from key opinion leaders (KOLs) in exploring these areas.
Achieve Life Sciences is optimistic about the potential of cytisinicline in combating nicotine dependence. The company is prioritizing smoking cessation as the initial focus. However, there has been interest from the vaping side of the opportunity, and a potential Phase 3 trial for vaping is under consideration. Bencich mentioned that the sample size for this potential trial would likely be similar to previous trials, with a single Phase 3 trial expected for approval.
Bencich also highlighted the company’s discussions with commercial innovation partners, emphasizing the need for a single global partner with strong U.S. capabilities. The company is considering specialty companies with a focus on CNS or addiction. In addition, Achieve Life Sciences has obtained pre-clearance from the FDA for a brand name, though final approval will only come after the completion of the NDA review.
The management expressed satisfaction with the progress of the program and the interest from commercialization organizations. The company is finalizing discussions with commercial partners, completing NDA preparations, and defining the regulatory pathway for cytisinicline in e-cigarette cessation. However, the exact timing of the NDA submission remains unspecified.
In light of the recent developments at Achieve Life Sciences, it’s crucial to keep an eye on the financial aspects of the company. According to InvestingPro data, Achieve Life Sciences has an adjusted market cap of $88.43M and a negative P/E ratio of -1.53, indicating that the company is not currently profitable. Over the last twelve months as of Q2 2023, the company’s operating income was at a negative $39.79M, with the price standing at 40.68% of its 52-week high.
From the InvestingPro Tips, we learn that Achieve Life Sciences maintains a healthier financial position by holding more cash than debt on its balance sheet. The company has also been consistently increasing its earnings per share, which is a positive indicator for potential investors. However, it’s important to note that the company has not been profitable over the last twelve months, and analysts do not anticipate it will be profitable this year.
For those interested in a deeper dive into the financial standing and future potential of Achieve Life Sciences, InvestingPro offers numerous additional tips and data points that can provide valuable insights. These include factors such as return on assets, return on book equity, and anticipated earnings revisions.
Full transcript – ACHV Q3 2023:
Operator: Greetings. Welcome to Achieve Life Sciences Third Quarter Earnings Conference Call and Webcast. [Operator Instructions] Please note this conference is being recorded. At this time, I’ll turn the conference over to Nicole Jones with Investor Relations. Nicole, you may now begin.
Nicole Jones: Thank you, operator, and thank you to everyone for joining the call today. Today from Achieve, we have John Bencich, Chief Executive Officer; Dr. Cindy Jacobs, President and Chief Medical Officer; and Jerry Wan, Principal Accounting Officer. Achieve’s management will be available for Q&A after the prepared remarks. I’d like to remind everyone that today’s conference call contains forward-looking statements based on current expectations. These statements are only predictions and actual results may vary materially from those projected. Please refer to Achieve documents available on our website and filed with the SEC concerning factors that could affect the company. I’ll now turn the call over to John.
John Bencich: Thank you, Nicole and thanks, everyone, for joining us today to review our third quarter highlights and the overall status of the cytisinicline program. Over the last quarter as well as throughout the entire year, significant progress has been made in establishing the foundation for the first novel nicotine dependence treatment in almost two decades. So far this year, with a small and efficient team of only 22 full-time employees, Achieve accomplished many significant milestones including the announcement of positive results from our second Phase 3 cytisinicline trial for smoking cessation and published results from our first Phase 3 trial in JAMA. Reported a statistically significant efficacy benefit in the Phase 2 ORCA-V1 trial, the first ever randomized controlled trial for e-cigarettes cessation. We’ve completed three additional clinical studies of over 100 subjects required for NDA submission, made significant progress on the compilation of the NDA, held numerous interactions and conducted three formal meetings with the agency to prepare for filing and approval in the U.S., including most recently a pre-NDA discussion that occurred at the end of October and increased outreach and further discussions with potential commercial organizations on the cytisinicline U.S. and global marketing opportunity. We believe pending FDA approval cytisinicline holds promise for providing a fresh start to the millions grappling with quitting smoking and vaping. There remain over 1 billion cigarette smokers around the globe. In the United States alone, over 28 million adult smoke combustible cigarettes and 11 million adult-based nicotine. The market potential for cytisinicline is substantial and its potential impact on global public health is unparalleled. We have strong confidence in cytisinicline’s effectiveness in assisting individuals who are motivated to quit smoking. Our Phase 3 clinical trial results demonstrate a significant advantage with smokers treated with cytisinicline being up to 8x more likely to successfully quit smoking compared to those receiving placebo. Notably, cytisinicline stands out from existing treatments due to its excellent tolerability with the most common adverse events affecting fewer than 10% of trial participants. We perceive a distinct opportunity with cytisinicline to reinvigorate the nicotine de-addiction market and make a profound impact on public health. By introducing this new treatment option, we anticipate a higher number of individuals will be encouraged to embark on a new quit attempt. With a product that is well tolerated, we anticipate a high level of compliance and adherence to treatment, thereby enhancing their chances of successfully quitting. Our confidence in cytisinicline is reinforced by leaders in the smoking-cessation community who have consistently shown their willingness to collaborate, express interest in new research and assist us in disseminating these crucial findings. During our engagements with this influential community, they have expressed that the goal for a new therapy should be to double the likelihood of a successful quit compared to behavioral support alone. Cytisinicline vastly exceeds this threshold with subjects in our ORCA studies treated with cytisinicline, having odds of quitting improved by upwards of 6x to 8x. This quarter, our research of the optimized dosing and administration of cytisinicline in U.S. subjects was published in the highly esteemed medical journal, JAMA. This recognition has made a significant impact garnering thousands of online views and being featured in more than 40 media outlets. Furthermore, during this quarter, Dr. Nancy Rigotti, an ORCA primary investigator and Professor of Medicine at Harvard Medical School and the Director of the Tobacco Research and Treatment Center at Massachusetts General Hospital presented for the first time, data results from the Phase 2 ORCA-V1 trial of cytisinicline for e-cigarettes cessation at the Society for Research on nicotine and tobacco annual European meeting. ORCA-V1 evaluated the safety and efficacy of cytisinicline treatment for 12 weeks compared to placebo in 160 adults who use nicotine e-cigarettes. Cytisinicline treated subjects experienced statistically significant cessation rate of approximately 32% compared to 15% in the placebo arm or 2.6x higher odds of quitting vaping. As seen across our development program, cytisinicline was very well tolerated and no treatment-related serious adverse events were reported. Our endeavors to combat the vaping epidemic have been met with strong support from government agencies, clinicians and prospective commercial partners, highlighting the pressing unmet need in this area. ORCA-V1 was the first randomized placebo-controlled trial to achieve success in demonstrating the efficacy of the treatment for addressing this type of nicotine dependence. These results are highlighted as there are currently no approved treatments tailored specifically for vaping cessation. The overall e-cigarette market continues to expand rapidly with the most recent prevalence rate in the U.S. indicating a 20% annual increase of adult users. While e-cigarettes can serve as a helpful tool for some transitioning away from combustible cigarettes, the long-term effects remain unknown. And many individuals aspire to quit nicotine altogether, which is precisely where cytisinicline can step in. We are assessing our clinical development strategy to pursue an on-label indication for e-cigarettes to patients and plan on holding an end of Phase 2 meeting with FDA in 2024 to discuss the requirements for approval. As there are no treatments approved for e-cigarettes decision, this is a recognized area of high unmet need and we will position it as such during our discussions with the FDA. Our goal is to expand the label of cytisinicline for specific promotions for e-cigarettes decision. Even though many healthcare providers may consider cytisinicline a viable option for treating various forms of nicotine dependence. As you may recall, ORCA-V1 was partially financed via non-dilutive grant funding from NIDA and NIH. We believe there may also be nondilutive funding opportunities available to support a future basing study. Our aspirations of changing public health hinge on the regulatory filing and successful approval of cytisinicline. To that end, we have been focused on continuing the work needed to support an NDA filing targeted in the first half of 2024. We are pleased to share that we have completed all of the in-clinic treatment portion of three NDA-enabling clinical trials that have been running over the course of this year. Specifically, these trials have been run to evaluate QT interval prolongation, steady-state pharmacokinetics in smokers and pharmacokinetic parameters in subjects with renal impairment. We expect final study reports from these trials to be available in early 2024. Additionally, last week, we held a pre-NDA meeting with the FDA. The FDA encourages this pre-submission engagement to solicit comments and clarification from the agency on the acceptability of key data including information that might become available for submission during NDA review. This initial discussion was constructive, an agreement was reached on many of the submission requirements. Dialogue with the FDA is ongoing and because of this, we aren’t able to provide additional details at this time. We will be in a position to provide an overview once discussions are finalized. The output of the pre-NDA discussion is critical to clarifying the final regulatory path of cytisinicline in the U.S. and will set the stage for how this product will progress through future market approvals around the globe. Additionally, these data points are important to furthering the discussions we are having with potential commercial organizations. Since ORCA-V1 and ORCA-3 have been released and ORCA-2 was published in JAMA. We have seen significant additional commercial interest in the cytisinicline program. As we have stated previously, we continue to believe the fifth asset in the hands of a larger organization will maximize the full commercial opportunity. So what are we looking for exactly? Our ideal partner would have global capabilities with an established footprint and strong commercial capabilities and resources to maximize the global health impact that cytisinicline offers. Given the substantial U.S. market opportunity, strong U.S. sales and marketing capabilities are an important attribute that we are seeking in our selection process. We are pleased with the dialogue and engagement with potential commercialization partners and are focused on continuing to move this process forward expeditiously. At this time, I will hand the call over to Jerry to review our financial highlights and results.
Jerry Wan: Thanks, John. I will be providing an update on our cash position as of September 30, 2023, and reviewing our operating expenses for the third quarter of 2023. As of September 30, 2023, the company’s cash, cash equivalents, short-term investments and restricted cash were $20 million compared to $24.8 million as of December 31, 2022. We believe our current cash balance is sufficient to provide us runway into the second half of 2024. With respect to our statement of operations, net loss decreased to $7.1 million for the quarter ended September 30, 2023, compared to $13.1 million for the same quarter of 2022. Net loss for the nine months ended September 30, 2023, decreased to $24.3 million compared to $31.1 million for the same period of 2022. In line with expectations, operating expenses continued to decrease for the third quarter of 2023 with the completion and wind down of both the ORCA-3 Phase 3 trial and the ORCA-V1 Phase 2 trial. We expect our quarterly operating expenses to remain lower in the fourth quarter as compared to the first half of 2023. The decrease in costs will be partially offset an associated increase in NDA supporting activities including the finalization of three NDA supportive clinical trials and other NDA preparation activities. That concludes my financial remarks and I will now turn the call back over to John.
John Bencich: Thanks, Jerry. As I stated at the beginning of the call, 2023 has been a remarkable year for Achieve and the cytisinicline development program. In the near term, we have three key priorities where we will focus our efforts. First, finalized discussions with preferred strategic commercial organizations; second, complete preparations to finalize the NDA submission and third, define the regulatory pathway for cytisinicline label expansion in e-cigarette cessation. We maintain our confidence in cytisinicline’s ability to change the face of public health and we appreciate your support as we work diligently to bring forward this important treatment. At this time, I’d now like to turn the call over to the operator for questions.
Operator: Thank you. [Operator Instructions] Our first question is from the line of Thomas Flaten with Lake Street. Please proceed with your question
Thomas Flaten: Guys, I appreciate you taking the questions. John, with respect to timing of the NDA submission, given that the data from the three supportive studies will be out in the first quarter, is second quarter most likely? I know you’re guiding the first half, but just some thoughts on that.
John Bencich: Yes. Thomas, thanks for the question there. So given that the discussions are ongoing with the agency, as we conclude the pre-NDA meeting, and we look to get final agreements and minutes out the other end. We’re not able to refine anything further on that. So we’ll have a future update as we kind of get through that final process and dialogue with the agency.
Thomas Flaten: And coming out of that October meeting, was there anything surprising any incremental studies that they requested or was it pretty straightforward?
John Bencich: I think in terms of the output, I think as we mentioned, the discussion was constructive. We did get agreement on many of the items that we were looking for. And there’s a few other pieces that we’re looking to get finalized and written documentation on. And so we’ll be able to provide a further update on that as we get through those final discussions.
Thomas Flaten: And then just one final question for me. Could you give us maybe a little assistance in mapping out spending between today and the submission?
John Bencich: Yes. So I think if you look at the third quarter in terms of kind of the decrease in burn that we saw from the first half of this year, I think you can expect that will continue through the fourth quarter of this year as well. So we will see that decline carry forward if you’re looking at kind of projecting that ahead. So I think that would be a good way to think about it at the moment.
Thomas Flaten: Excellent. Appreciate you taking the question. Thank you.
John Bencich: Thanks Thomas.
Operator: Our next question is from the line of Michael Higgins with Ladenburg Thalmann. Please proceed with your questions.
Michael Higgins: Thanks. Hi John, hey guys. Congrats on the continued to progress including your ION expenses that’s notable here in Q3 results and thanks for taking some questions here. If I could ask a bit more on the feedback and your progress with potential commercialization partners. Wondering how that’s coming along. And if you believe our discussions with the FDA will be wrapping up in first part of 2024, do you expect to have feedback from NDA NIH regarding vaping before you complete those potential commercialization conversations?
John Bencich: Michael, yes, thanks for the question. So on the vaping indication, what we’ve been guiding to is holding an end of Phase 2 meeting next year. In terms of further refining our timing on that, we can’t really provide that at the moment. Our focus will continue to be on the smoking cessation NDA as kind of that initial priority to make sure the path moving forward expeditiously.
Michael Higgins: Is it fair to say the partnering discussions would be separate for cigarette versus vaping?
John Bencich: The partnering discussions, I think we have seen a fair amount of interest coming from the vaping side of the opportunity. Smoking cessation will continue to be the core of that. And so I think in terms of the initial opportunity, that’s going to be the first piece to launch. And so both are important, but I think the smoking given kind of the near-term nature of it is going to be the majority of focus there.
Michael Higgins: That’s fair. Thanks. And then just to clarify for everyone on board here, the gating factors ahead of the NDA filing. Obviously, you have discussions with the agency. You’ve got some three studies reading out early next year. Are those the two primary drivers of this discussion with the agency, but anything else besides those three that you’re waiting on?
John Bencich: Yes. So those three are obviously critical in terms of having those key components that we knew were going to be needed for the NDA. I think as we finalize the pre-NDA discussions, we get those file written minutes, we’ll be able to clarify further timing on the NDA piece. And I think the key piece of this is getting clarity going forward and that feeds back into the partnering discussions and making sure that the path towards approval is fully clarified, and that’s exactly what we’re getting out of the pre-NDA meeting. Makes sense. Appreciate it. Thanks, guys.
John Bencich: Thank you.
Operator: Our next question is from the line of Francois Bridge with Oppenheimer. Please proceed with your questions.
Unidentified Analyst: Hi. This is Dan on for Frank. Thanks for taking my questions. Firstly, congrats on JAMA publication, also the ORCA-V2 presentation at the V1 presentation at the SRNT. Can you give us a sense of the KOL feedback that you’re hearing from these conferences? Anything in particular in terms of cytisinicline features, tolerability, efficacy that is standing out, that is coming up? Any color there?
John Bencich: Yes. Thanks for the question. I’m going to hand this over to Cindy.
Cindy Jacobs: Yes. Well, Nancy Rigatti actually presenting and our other KOLs are pretty excited as far as the efficacy that cytisinicline shows but actually, there are even more impressed and excited about the safety profile, which allows them individuals to stay on treatment and get the benefit. So it’s really a combination of the efficacy and safety profile that they are the most excited for smokers and in the future of vapors to actually have a new therapy to help their nicotine dependence.
Unidentified Analyst: Great. And just any updates on the FDA inspection readiness on the – Sopharma front? And also any updates regarding preparations with regard to supply chain, getting the registration batch are all those processes on track?
John Bencich: Yes. Thanks for the question there. So I think the Sopharma and CMC attributes are going to continue to be focus as we move forward through NDA submission. As we’ve indicated historically, we’ve been working very closely with Sopharma and their readiness efforts including numerous mock FDA inspection audit. So that work will continue. As we progress and Sopharma continues to be confident that they can be ready for a future inspection. But it will continue to be a high area of focus for us as we proceed.
Unidentified Analyst: Thank you. Thanks for taking my questions.
Operator: [Operator Instructions] The next question is from the line of John Vandermosten with Saks. Please proceed with your questions.
John Vandermosten: All right. Thank you. Is there any reason to think that the potential vaping Phase 3 trial would be much different from ORCA-3. Are there any considerations there? Might it be smaller or I know it’s kind of early, but just thinking ahead on that.
John Bencich: Yes. So in terms of overall sizing, I think looking back at ORCA-2 and ORCA-3 is probably a good proxy in terms of overall sample size. As we’ve indicated before, our belief is a single Phase 3 trial is what would be required for approval in this indication. But ultimately, we’ll need to get guidance from FDA on that. But the ultimate design, we’ll still be working on in terms of what that looks like. But yes, that sort of size is what you should anticipate.
John Vandermosten: Okay. Great. And I was doing some reading on varenicline and there’s thoughts that it could be used for other types of addiction, perhaps cocaine and things like that. Is that something that you might consider as well to pursue beyond nicotine addiction.
Cindy Jacobs: It’s Cindy. So we’ve had a lot of interest from our KOLs and other investigators of considering that once obviously approved for smoking cessation through brands and so we’re supportive in those types of investigators on trials to kind of look at the other areas of addiction that cytisinicline could be helpful. And with that, then watch and see what we should pursue as a company.
John Vandermosten: And is that something that you talked to with potential buyers at this point. I might those get split off you pursue that on your own and they lift out the nicotine addiction part? Or is that – would that kind of all go together, do you think? I mean, again, I know it’s early, but just I’m wondering kind of how the thought would be on that and maybe conversations that you’ve had.
John Bencich: Yes. So I think in terms of discussions with commercial innovation partners, I think this is really looking at the totality of this. We’re not looking at splitting this apart in terms of multiple pieces like as we indicated on a larger scale before we’ve had term sheet ex U.S. from parties, in particular, a lot of interest coming out of Asia. Our continued belief is that this asset belongs in the hands of a single global partner, one that does have strong U.S. capabilities to maximize the opportunity here in the U.S. And so that’s what we’re looking for. We think that really kind of resolves around the entirety of the asset, not covering it up into specific indications.
John Vandermosten: Okay. And then looking at the potential sales force that might work the best for this after approval, are there any characteristics that you kind of look forward? And I’m sure you have a number of suitors that you’re talking to and obviously, on your side, you want to see something that’s attractive there to know what you can target and negotiate hardest with. What are some of those features that you look for in the sales force that would allow cytisinicline to kind of layer on easily and have them be very effective.
John Bencich: Yes, I think when we look at this overall indication. I think historically, where we see it moving forward and will continue to be a primary care call point. So from our perspective, having reps on the ground that can hit that call point. This could be an asset that’s basically plugged and played into an existing sales force out there. We think that’s kind of the easiest path forward. But there could be other opportunities when you look at more specialty companies that have either a CNS focus or addiction focus. So I think there’s a number of angles, but I think a strong overlap with the call point is one of the key considerations for us.
John Vandermosten: Okay. And then any hints on a brand name that you guys might be working on or looking for?
John Bencich: We do. A good question. This is something that we precleared with the agency already. Obviously, it’s not fully blessed until the NDA review gets through the end. But that’s one of the components we did pretty clear early just to make sure that we have that ready to roll.
John Vandermosten: Great. All right. Thank you, John. Thank you, Cindy.
John Bencich: Thank you.
Operator: At this time, I will turn the floor back to management for closing remarks.
John Bencich: Yes. Thanks, operator, and thanks, everyone, for joining us today. We appreciate all the continued interest. It’s been a tremendous year with data coming out of not only our second confirmatory Phase 3 trial, but also the first ever randomized placebo-controlled trial in vaping and publication of our first Phase 3 trial in JAMA. So really excited about where the program sits today and the interest that we continue to see from commercialization organization. We look forward to driving this forward expeditiously and providing updates as we proceed. So thanks, everyone, again for joining us today.
Operator: Thank you. This will conclude today’s conference. You may disconnect your lines at this time. Thank you for your participation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.